Johnson & Johnson (TICKER: JNJ) Benchmark And Performance Data

there are 10 of samples in the benchmark for Johnson & Johnson in year 2022 in 2022. The total inventory for Johnson & Johnson was $9,344,000,000.00 in 2020. The total inventory for Johnson & Johnson was $9,020,000,000.00 in 2019. The total inventory for Johnson & Johnson was $8,765,000,000.00 in 2017. The total inventory for Johnson & Johnson was $8,599,000,000.00 in 2018. The total inventory for Johnson & Johnson was $8,184,000,000.00 in 2014. The total inventory for Johnson & Johnson was $8,144,000,000.00 in 2016. The total inventory for Johnson & Johnson was $8,053,000,000.00 in 2015. The total inventory for Johnson & Johnson was $7,878,000,000.00 in 2013. The total inventory for Johnson & Johnson was $7,495,000,000.00 in 2012. The total inventory for Johnson & Johnson was $10,387,000,000.00 in 2021. The sales, general, and administrative (SGA) for Johnson & Johnson was $24,659,000,000.00 in 2021. The sales, general, and administrative (SGA) for Johnson & Johnson was $22,540,000,000.00 in 2018. The sales, general, and administrative (SGA) for Johnson & Johnson was $22,178,000,000.00 in 2019. The sales, general, and administrative (SGA) for Johnson & Johnson was $22,084,000,000.00 in 2020. The sales, general, and administrative (SGA) for Johnson & Johnson was $21,954,000,000.00 in 2014. The sales, general, and administrative (SGA) for Johnson & Johnson was $21,830,000,000.00 in 2013. The sales, general, and administrative (SGA) for Johnson & Johnson was $21,520,000,000.00 in 2017. The sales, general, and administrative (SGA) for Johnson & Johnson was $21,203,000,000.00 in 2015. The sales, general, and administrative (SGA) for Johnson & Johnson was $20,869,000,000.00 in 2012. The sales, general, and administrative (SGA) for Johnson & Johnson was $20,067,000,000.00 in 2016. The sales, general, and administrative (SGA) for Johnson & Johnson was $$24,765,000,000 in 2022. The revenue volatility for Johnson & Johnson was 6.94% in 2022. The market capitalization for Johnson & Johnson was $467,100,134,228.00 in 2016. The market capitalization for Johnson & Johnson was $466,046,747,266.00 in 2015. The market capitalization for Johnson & Johnson was $461,848,529,176.00 in 2018. The market capitalization for Johnson & Johnson was $450,358,363,486.00 in 2014. The market capitalization for Johnson & Johnson was $433,825,657,534.00 in 2012. The market capitalization for Johnson & Johnson was $430,142,464,094.00 in 2020. The market capitalization for Johnson & Johnson was $429,502,827,647.00 in 2017. The market capitalization for Johnson & Johnson was $425,145,857,858.00 in 2013. The market capitalization for Johnson & Johnson was $405,107,464,940.00 in 2019. The market capitalization for Johnson & Johnson was $375,048,205,108.00 in 2021. The market capitalization for Johnson & Johnson was $$377,004,000,000 in 2022. The gross revenue for Johnson & Johnson was $93,775,000,000.00 in 2021. The gross revenue for Johnson & Johnson was $82,584,000,000.00 in 2020. The gross revenue for Johnson & Johnson was $82,059,000,000.00 in 2019. The gross revenue for Johnson & Johnson was $81,581,000,000.00 in 2018. The gross revenue for Johnson & Johnson was $76,450,000,000.00 in 2017. The gross revenue for Johnson & Johnson was $74,331,000,000.00 in 2014. The gross revenue for Johnson & Johnson was $71,890,000,000.00 in 2016. The gross revenue for Johnson & Johnson was $71,312,000,000.00 in 2013. The gross revenue for Johnson & Johnson was $70,074,000,000.00 in 2015. The gross revenue for Johnson & Johnson was $67,224,000,000.00 in 2012. The gross revenue for Johnson & Johnson was $$94,943,000,000 in 2022. The gross margin for Johnson & Johnson was $24.97% in 2022. The days sales outstanding for Johnson & Johnson was 60 days in 2022. The days payable outstanding for Johnson & Johnson was 134 days in 2022. The days of inventory for Johnson & Johnson was $134 in 2022. The cost of goods sold (COGS) for Johnson & Johnson was 32.74% in 2022. The cost of goods sold (COGS) for Johnson & Johnson was $29,855,000,000.00 in 2021. The cost of goods sold (COGS) for Johnson & Johnson was $28,427,000,000.00 in 2020. The cost of goods sold (COGS) for Johnson & Johnson was $27,556,000,000.00 in 2019. The cost of goods sold (COGS) for Johnson & Johnson was $27,091,000,000.00 in 2018. The cost of goods sold (COGS) for Johnson & Johnson was $25,439,000,000.00 in 2017. The cost of goods sold (COGS) for Johnson & Johnson was $22,746,000,000.00 in 2014. The cost of goods sold (COGS) for Johnson & Johnson was $22,342,000,000.00 in 2013. The cost of goods sold (COGS) for Johnson & Johnson was $21,789,000,000.00 in 2016. The cost of goods sold (COGS) for Johnson & Johnson was $21,658,000,000.00 in 2012. The cost of goods sold (COGS) for Johnson & Johnson was $21,536,000,000.00 in 2015. The cost of goods sold (COGS) for Johnson & Johnson was $$31,089,000,000 in 2022. The cash to cash cycle time for Johnson & Johnson was 60 in 2022. The annual percentage growth rate of Johnson & Johnson was -0.01% in 2022. Johnson & Johnson in its benchmark peer group, had rank 8 for cost of goods sold as a percent of revenue in 2022. Johnson & Johnson in its benchmark peer group, had rank 6 for sales growth in 2022. Johnson & Johnson in its benchmark peer group, had rank 6 days for days of inventory in 2022. Johnson & Johnson in its benchmark peer group, had rank 3 for cash to cash cycle time in 2022. Johnson & Johnson in its benchmark peer group, had rank 3 days for days sales outstanding in 2022. Johnson & Johnson in its benchmark peer group, had rank 2 for gross revenue in 2022. Johnson & Johnson headquarters region is East. Johnson & Johnson has ticker symbol JNJ. Johnson & Johnson has the following profile: Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. This segment also offers STAYFREE and CAREFREE sanitary pads; o. b.. Johnson & Johnson has primary indstury Drug Manufacturers - General. Johnson & Johnson had a $$5,387,000,000 gap between actual performance and next performance rank for gross revenue in competitive benchmarking in 2022. Johnson & Johnson had Organon, and Eli Lilly, and AbbVie, and Pfizer, and Bristol-Myers Squibb, and Amgen, and Gilead Sciences, and Biogen, and Johnson & Johnson, and Merck benchmark peer companies for its SIC code in 2022. Johnson & Johnson had 5.89% gap between actual performance and next performance rank for cost of goods sold as a percent of revenue in competitive benchmarking in 2022. Johnson & Johnson had 5.61% gap between actual performance and next performance rank for gross margin in competitive benchmarking in 2022. Johnson & Johnson had 5 days gap between actual performance and next performance rank for days of inventory in competitive benchmarking in 2022. Johnson & Johnson had 4 days gap between actual performance and next performance rank for days sales outstanding in competitive benchmarking in 2022. Johnson & Johnson had 23 days gap between actual performance and next performance rank for cash to cash in competitive benchmarking in 2022. Johnson & Johnson had 155,800 number of employees in 2022. Johnson & Johnson had 0.22% gap between actual performance and next performance rank for sales volatility in competitive benchmarking in 2022. Johnson & Johnson had 0.00% gap between actual performance and next performance rank for sales growth in competitive benchmarking in 2022. Johnson & Johnson can reduce overall cost by $$10,396,000,000 by improving both COGS and SGA to next benchmark tier in 2022. Johnson & Johnson can reduce inventory with practices including SKU Reduction in 2022. Johnson & Johnson can reduce inventory with practices including Reduce Manufacturing Latency in 2022. Johnson & Johnson can reduce inventory with practices including Forecast Accuracy in 2022. Johnson & Johnson can reduce inventory with practices including Demand Shaping in 2022. Johnson & Johnson can reduce days sales outstanding with practices including in 2022. Johnson & Johnson can increase sales revenue by $$5,387,000,000 improving sales performance to next benchmark tier in 2022. Johnson & Johnson can increase revenue growth by $$2,000,000 by improving growth performance to next benchmark tier in 2022. Johnson & Johnson can increase overall revenue by $$5,389,000,000 by improving both growth and sales performance to next benchmark tier in 2022. Johnson & Johnson can increase days payables outstanding with practices including Strategic Sourcing in 2022. Johnson & Johnson can increase days payables outstanding by $1,717,000,000 days by increasing days payables outstanding to next benchmark tier in 2022. Johnson & Johnson can improve total financial performance by $$19,765,000,000 by improving revenue, costs, and working capital in 2022. Johnson & Johnson can decrease overall working capital by $$3,980,000,000 by improving inventory, payables and receivables to next benchmark tier in 2022. Johnson & Johnson can decrease inventory days by $1,301,000,000 days by reducing inventory days to next benchmark tier in 2022. Johnson & Johnson can decrease days sales outstanding by $962,000,000 days by reducing days sales outstanding to next benchmark tier in 2022. Johnson & Johnson can accelerate revenue growth practices including Revenue-optimized Planning in 2022. Johnson & Johnson can accelerate revenue growth practices including Pricing Optimization in 2022. Johnson & Johnson can accelerate revenue growth practices including Accelerate Design Pipeline in 2022. 82 days was the measured parity or middle performance level for cash to cash cycle time in Johnson & Johnson's peer group in 2022. 79 days was the measured superior or top ten performance level for days of inventory in Johnson & Johnson's peer group in 2022. 68 days was the measured advantage or top third performance level for cash to cash cycle time in Johnson & Johnson's peer group in 2022. 66 days was the measured parity or middle performance level for days sales outstanding in Johnson & Johnson's peer group in 2022. 61 days was the measured advantage or top third performance level for days sales outstanding in Johnson & Johnson's peer group in 2022. 6.73% was the measured superior or top ten performance level for sales volatility in Johnson & Johnson's peer group in 2022. 56 days was the measured superior or top ten performance level for days sales outstanding in Johnson & Johnson's peer group in 2022. 37.46% was the measured superior or top ten performance level for gross margin in Johnson & Johnson's peer group in 2022. 37 days was the measured superior or top ten performance level for cash to cash cycle time in Johnson & Johnson's peer group in 2022. 26.85% was the measured parity or middle performance level for cost of goods sold as a percent of revenue in Johnson & Johnson's peer group in 2022. 22.98% was the measured advantage or top third performance level for cost of goods sold as a percent of revenue in Johnson & Johnson's peer group in 2022. 21.84% was the measured superior or top ten performance level for cost of goods sold as a percent of revenue in Johnson & Johnson's peer group in 2022. 14.35% was the measured parity or middle performance level for sales volatility in Johnson & Johnson's peer group in 2022. 129 days was the measured parity or middle performance level for days of inventory in Johnson & Johnson's peer group in 2022. 100 days was the measured advantage or top third performance level for days of inventory in Johnson & Johnson's peer group in 2022. 10.93% was the measured advantage or top third performance level for sales volatility in Johnson & Johnson's peer group in 2022. 0.03% was the measured superior or top ten performance level for sales growth in Johnson & Johnson's peer group in 2022. 0.00% was the measured advantage or top third performance level for sales growth in Johnson & Johnson's peer group in 2022. -0.01% was the measured parity or middle performance level for sales growth in Johnson & Johnson's peer group in 2022. $33.59% was the measured advantage or top third performance level for gross margin in Johnson & Johnson's peer group in 2022. $30.58% was the measured parity or middle performance level for gross margin in Johnson & Johnson's peer group in 2022. $$95,482,000,000 was the measured superior or top ten performance level for gross revenue in Johnson & Johnson's peer group in 2022. $$58,423,000,000 was the measured advantage or top third performance level for gross revenue in Johnson & Johnson's peer group. $$37,350,000,000 was the measured parity or middle performance level for gross revenue in Johnson & Johnson's peer group in 2022.